BioRelix, Inc. and Dalton Medicinal Chemistry Partners Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology

Published: Nov 13, 2007

NEW HAVEN, CT, and TORONTO, Nov. 13 /CNW/ - BioRelix, pioneers in the discovery and development of RiboSwitch based therapeutic agents and Dalton Medicinal Chemistry, have jointly announced a research collaboration to discover new therapeutics.

Back to news